Pfizers Becosules Brand Retains Top Slot: Survey

Pfizer's multi-vitamin Becosules continues to remain the top selling brand according to market research agency ORG Marg for the period till, August 2001. Among the faster growing brands is Glaxo's anti-ulcerant Zinetac (ranitidine) which saw a growth of 20 per cent for the same period.

Becosules, at Rs 77 crore turnover, saw a growth of 4.6 per cent growth. The number two product is Corex, a cough syrup, again from Pfizer Ltd which, at Rs 74 crore turnover, saw a two per cent growth. In the third position is Novartis' non-steroidal anti-inflammatory drug Voveran. At Rs 69 crore turnover, the drug saw 4.4 per cent growth.

Alembic's Althrocin takes the fourth position at Rs 65 crore turnover with a dip in growth of three per cent. Zinetac stands fifth in the ranking. Ranbaxy's Sporidex, an antibiotic, comes sixth with a turnover of Rs 61 crore and again a negative growth of four per cent.

Ranbaxy's ciprofloxacin brand Cifran has registered a negative annual growth of 11.7 per cent for the same period and is the last in the top ten products list. According to analysts, the anti-infectives market has been witnessing declining sales volumes and margins due to the presence of an abundance of branded and unbranded products forcing to cut prices. "As a segment, anti-infectives has a short life span," said an analyst with a private broking firm.

Ranbaxy has recently filed exclusive marketing rights (EMR) for Cifran OD a once-a-day formulation for ciprofloxacin. Ciprofloxacin faces competition from local and multinational players alike. The Ahmedabad-based Torrent Pharmaceuticals is also expected to introduce its once-a-day dosage of ciprofloxacin.

The Himalaya Drugs Company's Liv-52, health supplement of liver diseases, stands seventh with a turnover of Rs 58.4 crore and a growth of three per cent. Last year, Liv 52 was the fourth largest in terms of turnover. In the eighth position comes Taxim of Alkem Laboratories with Rs 57.9 crore turnover with a minus 9 per cent growth. Betnesol (betamethasone) of Glaxo at the ninth position saw a 13.6 per cent growth and has an annual turnover of Rs 56.6 crore.

image
Business Standard
177 22
Business Standard

Pfizers Becosules Brand Retains Top Slot: Survey

BUSINESS STANDARD 



Pfizer's multi-vitamin Becosules continues to remain the top selling brand according to market research agency ORG Marg for the period till, August 2001. Among the faster growing brands is Glaxo's anti-ulcerant Zinetac (ranitidine) which saw a growth of 20 per cent for the same period.

Becosules, at Rs 77 crore turnover, saw a growth of 4.6 per cent growth. The number two product is Corex, a cough syrup, again from Pfizer Ltd which, at Rs 74 crore turnover, saw a two per cent growth. In the third position is Novartis' non-steroidal anti-inflammatory drug Voveran. At Rs 69 crore turnover, the drug saw 4.4 per cent growth.

Alembic's Althrocin takes the fourth position at Rs 65 crore turnover with a dip in growth of three per cent. Zinetac stands fifth in the ranking. Ranbaxy's Sporidex, an antibiotic, comes sixth with a turnover of Rs 61 crore and again a negative growth of four per cent.

Ranbaxy's ciprofloxacin brand Cifran has registered a negative annual growth of 11.7 per cent for the same period and is the last in the top ten products list. According to analysts, the anti-infectives market has been witnessing declining sales volumes and margins due to the presence of an abundance of branded and unbranded products forcing to cut prices. "As a segment, anti-infectives has a short life span," said an analyst with a private broking firm.

Ranbaxy has recently filed exclusive marketing rights (EMR) for Cifran OD a once-a-day formulation for ciprofloxacin. Ciprofloxacin faces competition from local and multinational players alike. The Ahmedabad-based Torrent Pharmaceuticals is also expected to introduce its once-a-day dosage of ciprofloxacin.

The Himalaya Drugs Company's Liv-52, health supplement of liver diseases, stands seventh with a turnover of Rs 58.4 crore and a growth of three per cent. Last year, Liv 52 was the fourth largest in terms of turnover. In the eighth position comes Taxim of Alkem Laboratories with Rs 57.9 crore turnover with a minus 9 per cent growth. Betnesol (betamethasone) of Glaxo at the ninth position saw a 13.6 per cent growth and has an annual turnover of Rs 56.6 crore.

RECOMMENDED FOR YOU

Pfizers Becosules Brand Retains Top Slot: Survey

Pfizers Becosules Brand Retains Top Slot: Survey

Pfizer's multi-vitamin Becosules continues to remain the top selling brand according to market research agency ORG Marg for the period till, August 2001. Among the faster growing brands is Glaxo's anti-ulcerant Zinetac (ranitidine) which saw a growth of 20 per cent for the same period.

Becosules, at Rs 77 crore turnover, saw a growth of 4.6 per cent growth. The number two product is Corex, a cough syrup, again from Pfizer Ltd which, at Rs 74 crore turnover, saw a two per cent growth. In the third position is Novartis' non-steroidal anti-inflammatory drug Voveran. At Rs 69 crore turnover, the drug saw 4.4 per cent growth.

Alembic's Althrocin takes the fourth position at Rs 65 crore turnover with a dip in growth of three per cent. Zinetac stands fifth in the ranking. Ranbaxy's Sporidex, an antibiotic, comes sixth with a turnover of Rs 61 crore and again a negative growth of four per cent.

Ranbaxy's ciprofloxacin brand Cifran has registered a negative annual growth of 11.7 per cent for the same period and is the last in the top ten products list. According to analysts, the anti-infectives market has been witnessing declining sales volumes and margins due to the presence of an abundance of branded and unbranded products forcing to cut prices. "As a segment, anti-infectives has a short life span," said an analyst with a private broking firm.

Ranbaxy has recently filed exclusive marketing rights (EMR) for Cifran OD a once-a-day formulation for ciprofloxacin. Ciprofloxacin faces competition from local and multinational players alike. The Ahmedabad-based Torrent Pharmaceuticals is also expected to introduce its once-a-day dosage of ciprofloxacin.

The Himalaya Drugs Company's Liv-52, health supplement of liver diseases, stands seventh with a turnover of Rs 58.4 crore and a growth of three per cent. Last year, Liv 52 was the fourth largest in terms of turnover. In the eighth position comes Taxim of Alkem Laboratories with Rs 57.9 crore turnover with a minus 9 per cent growth. Betnesol (betamethasone) of Glaxo at the ninth position saw a 13.6 per cent growth and has an annual turnover of Rs 56.6 crore.

image
Business Standard
177 22
Widgets Magazine

More News

Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard